Iris Melanoma Clinical Trial
Official title:
Phase II Study of IMC-A12 in Metastatic Uveal Melanoma
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PRIMARY OBJECTIVES:
I. To determine the response rate of metastatic uveal melanoma when treated with IMC-A12
(cixutumumab).
II. To determine the safety and tolerability of IMC-A12 in patients with metastatic uveal
melanoma.
SECONDARY OBJECTIVES:
I. To determine the disease control rate of patients treated with IMC-A12. II. To determine
the duration of response of patients treated with IMC-A12. III. To determine the
progression-free survival and overall survival of patients treated with IMC-A12.
TERTIARY OBJECTIVES:
I. To correlate the presence of GNAQ and GNA11 mutations with response to IMC-A12.
II. To correlate the expression of IGF-1R with response to IMC-A12. III. To determine the
effect of IMC-A12 on expression of proteins involved in initiation, growth, and spread of
uveal melanoma cells.
IV. To determine resistance mechanisms to IMC-A12.
OUTLINE: This is a multicenter study.
Patients receive cixutumumab intravenously (IV) over 1 hour on days 1 and 15. Courses repeat
every 4 weeks in the absence of disease progression or unacceptable toxicity.
Archived and fresh tumor tissue and serum samples may be collected for correlative studies.
After completion of study treatment, patients are followed up for 30 days and then every 3
months for 1 year.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
| Terminated |
NCT02336763 -
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
|
N/A | |
| Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
| Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT02068586 -
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
|
Phase 2 | |
| Completed |
NCT01100528 -
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
|
Phase 2 | |
| Completed |
NCT00085189 -
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT01143402 -
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
| Completed |
NCT00450255 -
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00089063 -
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
|
Phase 2 | |
| Completed |
NCT00243061 -
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
Phase 2 | |
| Completed |
NCT01989572 -
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
|
Phase 3 | |
| Completed |
NCT00329641 -
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
|
Phase 2 | |
| Terminated |
NCT01730157 -
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
|
Phase 0 |